AstraZeneca 'aims to deliver' on European Union contract after report of more delays

Lawrence Kim
Февраля 27, 2021

In late January, President Emmanuel Macron referred to the vaccine "quasi-ineffective" for older people in comments to reporters, drawing criticism from the United Kingdom government for what was seen as unjustified undermining of the Oxford jab.

The spokesperson said: "AstraZeneca confirms today [Wednesday] that its most recent Q2 forecast for the delivery of its COVID-19 vaccine aims to deliver in line with its contract with the European Commission".

The pledge was in line with previous statements from the Anglo-Swedish drugmaker, which has long said it will not be able to fulfil the target of 90 million doses in the first quarter. AstraZeneca's vaccine was authorised in late January.

The European Union is facing another hold-up in deliveries of AstraZeneca's coronavirus vaccine.

Canada has secured access to 20 million doses of the AstraZeneca vaccine.

The French liberal MEP added that this will lead to further tensions with the company.

The expected shortfall, which has not previously been reported, follows a big reduction in supplies in the first quarter and could hit the EU's ability to meet its target of vaccinating 70% of adults by summer.

Responding to news of AZ's production issues, European Commission chief Ursula von der Leyen told the German publication Augsburger Allgemeine that the "vaccine manufacturers are our partners in this pandemic and they have also never faced such a challenge", as quoted by AFP.

A vail of the Oxford-AstraZeneca COVID-19 vaccine is seen at Basingstoke Fire Station, in Basingstoke, Britain February 4, 2021.

The additional problems of vaccine acceptance and slow national vaccination programmes add up to the hardships in ensuring timely supplies.

Sharma said the vaccines are about 62 per cent effective in preventing symptomatic cases of COVID-19, much lower than the Pfizer/BioNTech and Moderna vaccines.

During his defence, Soriot downplayed the problems experienced by AstraZeneca that ultimately affected the European Union supply chain. France has received more than 700,000 doses of AstraZeneca's vaccine.

It turns out that some of the production sites have delivered this assumption and other sites have delivered half of the assumption. By subscribing, you can help us get the story right. "It's pretty simple, it's just simple math", he said.

Health authorities in Germany and other countries have raised concerns that AstraZeneca didn't test the vaccine in enough older people to prove it works for them, and indicated they would not recommend it for people over 65.

None of the approved COVID vaccines are manufactured in Canada.

Other reports by

Discuss This Article